title: Radiotherapy options after breast-conserving surgery: how can selection of patients be refined?
authors.affiliation: Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
authors.forename: Pelagia G
authors.initials: PG
authors.lastname: Tsoutsou
authors.forename: Wendy
authors.initials: W
authors.lastname: Jeanneret Sozzi
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Delaloye
authors.forename: Jean
authors.initials: J
authors.lastname: Bourhis
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D011960:Receptors, Estrogen / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D013629:Tamoxifen